Overview

A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers.

Status:
Recruiting
Trial end date:
2022-12-16
Target enrollment:
Participant gender:
Summary
To evaluate the influence of BR1017-1 and BR1017-2 on pharmacokinetics and safety when administered separately or co-administered to healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Treatments:
Atorvastatin
Ezetimibe